Clinical aspects of PCSK9
Authors:
- Bertrand CariouBCBertrand Cariou
- Cédric Le MayCMCédric Le May
- Philippe CostetPCPhilippe Costet
- 1 June 2011
- journal article
- review article
- Published by Elsevier in Atherosclerosis
- Vol. 216 (2) , 258-265
Abstract
No abstract availableKeywords
Funding Information
- Fondation pour la Recherche Médicale
- Fondation de France
This publication has 82 references indexed in Scilit:
- Molecular Spectrum of Autosomal Dominant Hypercholesterolemia in FranceHuman Mutation, 2010
- A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primatesProceedings of the National Academy of Sciences of the United States of America, 2009
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primatesProceedings of the National Academy of Sciences, 2008
- Molecular basis for LDL receptor recognition by PCSK9Proceedings of the National Academy of Sciences, 2008
- Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading ActivityBiochemistry, 2008
- The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domainProceedings of the National Academy of Sciences, 2007
- Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activityBiochemical Journal, 2007
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9Proceedings of the National Academy of Sciences, 2005
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003